CAMP-specific 3',5'-cyclic phosphodiesterase 4D (PDE4D)

CAMP-specific 3',5'-cyclic phosphodiesterase 4D (PDE4D) is a member of the phosphodiesterase 4 (PDE4) subfamily, enzymes that hydrolyze cyclic AMP (cAMP) to 5'-AMP, thereby regulating intracellular second messenger levels critical for numerous signaling pathways[2][3][6]. PDE4D plays key roles in vascular biology, neuronal signaling, and immune modulation[2][6]. It exists in multiple isoforms with tissue-specific expression and functional diversity, impacting processes including memory, inflammation, and cell proliferation[2][6]. PDE4D is a validated therapeutic target for disorders such as depression, inflammation, asthma, and some neuropsychiatric and neurodegenerative conditions[6]. Pharmacological inhibition of PDE4D enhances cAMP signaling but is limited by dose-dependent gastrointestinal side effects, particularly emesis, attributed to this isoform[5][6]. Distinct roles for its isoforms, including PDE4D7 in prostate cancer, are under investigation for both therapeutic and diagnostic purposes[6].

Other names

Phosphodiesterase 4DPDE4D3',5'-cyclic-AMP phosphodiesterase 4DCyclic AMP-specific phosphodiesterase 4DcAMP-specific 3',5'-cyclic phosphodiesterase 4D

Inhibition of PDE4D increases intracellular cAMP, enhancing downstream PKA signaling. Drugs targeting PDE4D act as competitive inhibitors at the catalytic site. Some drugs act as allosteric modulators interacting with unique regulatory domains (e.g., UCR2 domain). Enhanced cAMP levels modulate inflammation, cognition, and immune responses.